TCON: TRACON P/S Multiple
TRACON Pharmaceuticals management is finalizing asset liquidation following the suspension of core programs, which is directly impacting the share price. The market cap-to-revenue ratio demonstrates volatility, with the current level standing at 0.00. The company previously relied on low molecule testing costs and inelastic demand in oncology, while simultaneously implementing energy saving and safe chemical disposal in its laboratories.
Analytical breakdowns for TRACON (TCON)
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital TRACON Pharmaceuticals|TCON - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio TRACON Pharmaceuticals, Inc|TCON - Company Aggregate Debts|Debts to Book Value TRACON|TCON - Company Long-Term Liabilities|Company Short-Term Debts TRACON Pharmaceuticals|Intermediate Liquidity Ratio traconpharma.com
- earnings and valuation multiples information:
TCON - Net Profit|Company Profit Forecast TRACON Pharmaceuticals|TCON - P/E Multiple|Projected Price to Earnings TRACON Pharmaceuticals Inc.|TCON - PEG Multiple|EV/EBITDA Multiple TRACON|TCON - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months TRACON Pharmaceuticals|TCON - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months traconpharma.com|TCON - Net earnings per share growth this year|Projected earnings per share increase next year TRACON Pharmaceuticals
- total revenue and sales volume data:
General company analysis:TCON - traconpharma.com
Low fundamental multiples in this case do not signal undervaluation, but rather reflect a critical breakdown of the business model. Analyzing the enterprise value-to-revenue ratio, an investor sees the market valuation of every dollar of sales, which for TRACON Pharmaceuticals (TCON) is plummeting amid failed clinical trials and a genuine threat of total liquidation.
Who TRACON Pharmaceuticals competes with
TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|P/S Multiple QGEN (Qiagen)|P/S Multiple Ionis Pharmaceuticals, Inc. IONS|RGEN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio RNA (Avidity Corp)|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Market Cap to Revenue genedx.com|RARE (Ultragenyx) - P/S Multiple|P/S Multiple Beam Therapeutics Inc|P/S Multiple SRPT|Market Cap to Revenue Twist Bioscience Corp TWST|P/S Multiple TXG (10x Genomics, Inc.)|intelliatx.com (NTLA) - Price to Sales|STOK: Market Cap to Revenue|BLFS - P/S Multiple|WVE (Wave Life Sciences Corp) - Market Cap to Revenue|MAZE: Market Cap to Sales Volume|SION (Sionna Therapeutics Inc) - P/S Multiple|primemedicine.com (PRME) - Price-to-Revenue Coefficient|P/S Multiple TSHA|Market Cap to Revenue uniQure NV QURE|P/S Multiple MGTX (MeiraGTx PLC)|P/S Multiple REGENXBIO Corp RGNX|SLDB - Price-to-Revenue Ratio|OCGN: Price-to-Revenue Ratio|PacBio (PACB) - Price-to-Revenue Ratio|BNTC - Price-to-Revenue Coefficient|Market Cap to Revenue DSGN|RCKT (Rocket Corp) - Market Cap to Sales Volume|P/S Multiple FDMT|Market Cap to Revenue lexeotx.com LXEO|Price-to-Revenue Ratio Korro Bio KRRO|Editas Medicine Inc (EDIT) - Price to Sales|SLN - Price-to-Revenue Ratio|PRQR (ProQR Therapeutics N.V.) - Market Cap to Revenue Ratio|CDXS: P/S Multiple|Market Cap to Revenue Ratio SGMO|Price-to-Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Revenue Ratio MGX (Metagenomi Inc.)|P/S Multiple DTIL|P/S Multiple generationbio.com (GBIO)|Boundless Bio, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XCUR (Exicure Inc.)|IMNN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PHIO (Phio Pharmaceuticals)|MBIO: P/S Multiple|TransCode Therapeutics, Inc. (RNAZ) - P/S Multiple|BNGO (Bionano Genomics Inc.) - P/S Multiple|Market Cap to Revenue adnas.com (APDN)|Price-to-Revenue Ratio bluebird bio (BLUE)|IPA - Price to Sales|Price-to-Revenue Ratio Omega OMGA|OMIC: Market Cap to Revenue Ratio|RGLS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SYRS (syros.com)|Telesis Bio (TBIO) - Price-to-Revenue Ratio|Price-to-Sales Ratio UBX (Unity Biotechnology Inc.)
